We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.
Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorisation of semaglutide for the treatment of adults with type II diabetes mellitus.
Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.
В сфере лечения заболеваний крови много инноваций. Американский Forbes описал самые примечательные
Foreign Stock Roundup: Bank of Montreal Q4 Earnings Decline, Rio Tinto Lowers '17 Capital Spending Target
Investors in Europe remained focused on Brexit negotiations and the Senate's decision to approve a new tax Bill last week.
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.
Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.
Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.
Dow Soars Past 24K; Finishes 8th Month in the Green
As we enter the last month of the year, here is a look at some pharma and biotech companies including Amgen (AMGN) that await a decision from the FDA for label expansions or new drugs.
Most drug companies with a larger market cap have seen their share price rising this year. However, a couple of large-cap pharma companies have witnessed a downside this year.
Gillian Blease/Getty Images Today, 437 million people worldwide have type 1 or type 2 diabetes. New estimates published this month show that three-quarters of a billion people could have the disease by 2045 — and cities are the front line of this challenge. As the growth fast becomes unmanageable for health systems, shortening the lives of millions of urban citizens and constraining economic growth, Novo Nordisk is working with a coalition of major cities to bend the curve on type 2 diabetes. We’re calling for local political and health leaders of all cities to ask what it will take to change the trajectory of the disease in their area and to put into practice the new models that we are forging. A rapidly urbanizing world is changing not just where we live but also how we live. As my predecessor at Novo Nordisk wrote, the way cities are designed, built, and run creates health benefits for citizens — but critically it also creates risks. Towns and cities, where half of the world’s population now lives, are home to two-thirds of people with diabetes. That’s why when we initiated the Cities Changing Diabetes program in 2014, we set out to put a spotlight on urban diabetes. This effort has grown into a global partnership of nine major cities, home to over 75 million people, and over 100 expert partners united in the fight against urban diabetes. Without concerted action, health systems around the world will reach a point in coming decades when they won’t be able to effectively treat patients sustainably. We conservatively estimate that the related costs of diabetes — including medication, supplies, hospital care, and the treatment of complications — will exceed $1 trillion a year by 2045. The catastrophic rise in diabetes won’t be stemmed by medicine alone. That’s why cities need to work together with a broad alliance of health care leaders and community organizers. Here’s what we’ve learned over the past two years of running the program about how cities can push back the disease: Focus on the most significant modifiable driver of the condition: obesity. We developed a new projection tool, which plots the trajectory of diabetes prevalence over time. For the first time, it illustrates how reducing the prevalence of obesity would reduce the burden of diabetes, in terms of the number of people with the disease and the costs to the health system. This can be used at a global, country, or city level to help see what it will take to bend the curve on diabetes and to set goals. For example, a 25% reduction of the number of obese adults in Johannesburg would cause the diabetes-prevalence curve to level off at one in eight adults in 2045. Even greater action is needed to bend the curve in Tianjin, where genetic factors mean people are more prone to diabetes at lower body-mass-index (BMI) levels, and in Mexico, where diabetes is already the number one cause of death. Understand the social and cultural factors that present the greatest risk and vulnerability. To hold back the rise in diabetes we have to be concerned not only about the most effective treatment but also with preventing people from getting diabetes in the first place. That’s why the focus on risk factors has become so important to tackling diabetes. We have learned that social and cultural factors in cities — including employment status, long commutes, cultures around food and population, and migration dynamics — can play such a significant role in putting people at risk of the disease. Fieldwork has revealed that some of the most vulnerable groups had never previously been on the radar of public health experts. For instance, Houston health officials were completely caught off guard by the revelation that the groups most at risk weren’t just the poor; they also included affluent professionals who engaged infrequently with the health system. In Shanghai, fieldwork revealed that those most at risk included middle-class families who were consciously concealing early symptoms, even from each other, because diabetes carries a social stigma in China. Building on our early research, and in partnership with University College London (UCL), this year we’ve developed the urban diabetes risk-assessment tool, which provides an easy-to-use way of understanding what the priority areas of risk are for any population. Vancouver is now pioneering this new research approach to engage citizens in the effort to help identify the most significant local vulnerabilities and then co-create interventions likely to be effective in the city. In taking action, draw on practices that have already proven to be effective. Partner cities have begun to take action in four areas: Health-promoting policy. Health inequalities exist, even in cities said to have the healthiest citizens in the world. Copenhagen, for example, has used learnings from the vulnerability assessment in developing the Copenhagen Diabetes Action Plan. Its key aim is to tackle the inequality that exists in diabetes prevalence and outcomes among adults in the city by focusing on the Copenhageners with the greatest needs. This has led to the creation of a new Center for Diabetes that brings together different expertise in preventing and treating the disease, new health-promotion initiatives aimed at socially disadvantaged neighborhoods, and community-wide engagement to establish sustained lifestyle changes among at-risk young people. Community involvement in health. An innovative example is Houston’s approach to engaging the faith community in health care. More than 50% of Houstonians regularly attend a house of faith. So under the leadership of the city’s health department, a Faith and Diabetes Summit was held whose 100-plus participants included leaders of the Buddhist, Muslim, Hindu, Jewish, and Christian communities. The next step is a six-week, train-the-trainer course that prepares two congregational members from different houses of faith to implement prevention programs among their peers. Urban planning. Engaging those shaping the urban environment through its transport systems and architecture is crucial given how much city design affects diabetes and obesity risk. In partnership with the global urban design consultancy Gehl and C40, the city climate network, Cities Changing Diabetes recently held an interactive three-day course in Copenhagen for urban planners, engineers, and architects from Barcelona, Bangalore, Bogotá, Cape Town, Rio de Janeiro and Vancouver. Five key takeaways applicable to any city emerged from concrete examples shared during the session. Examples ranged from how using new metrics on people spending time in public spaces led to the pedestrianization of New York City’s Times Square to how cultural events designed to attract people to car-free streets in Denver led to a 62% increase in pedestrian activity and a healthier downtown. Strengthening health systems. The first two Chinese cities to join the program, Shanghai and Tianjin, have both used their research into risk and vulnerability to inform significant interventions to strengthen their city health systems. In Tianjin, a train-the-trainer approach was established to build diabetes capacity and specialist skills among a group of primary care providers, enabling them to reach more people earlier in the course of the condition. Shanghai responded to findings that one-third of those with diabetes are undiagnosed by putting in place screening programs to reach 300,000 people at high risk of developing diabetes. New data from the modeling shows that to bend the curve on diabetes we must set an ambitious goal: reaching a point where no more than one in 10 adults globally has diabetes. That means we need to take aggressive actions to reduce obesity by 25% globally by 2045. Achieving this could stop 110 million people from developing diabetes between now and 2045 and ensure that health care systems can focus on delivering the best outcomes for those with the disease. The methods and tools we have collectively forged are contained in the Urban Diabetes Toolbox. We are sharing the toolbox so that city and health leaders in any city can set goals and establish an action plan for what it will take to respond to this public health emergency. As a company whose specialism for almost 100 years has been diabetes, we are uniquely positioned to help lead the battle against this disease. We believe we have not just a moral responsibility but also a compelling business reason to do so. Our ability to continue to deliver innovative products that benefit patients relies on strong, stable health systems. Unless the diabetes epidemic is brought under control, it will threaten the very viability of health systems around the world. That’s why we call on every city to ask itself: “What will it take to bend the curve on diabetes in our city?”
Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.
The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel
Top Analyst Reports for TOTAL S.A., Humana & Novo Nordisk
Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.